In order to ensure the preparation of the reports on emerging health technologies referred to in Article 22 of Regulation (EU) 2021/2282, the preparation of the annual work programme of the Coordination Group, its adoption and the adoption of its amendments and to enable the Coordination Group to provide the recommendation referred to in Article 7(4) of Regulation (EU) 2021/2282, the HTA secretariat should share the information provided by the European Medicines Agency related to the planning and forecast of the joint clinical assessments and joint scientific consultations, as well as the information on the medical devices and in vitro diagnostic medical devices referred to in Article 7(1), points (c) and (d), of Regulation (EU) 2021/2282 as appropriate with the Coordination Group and/or its relevant subgroups established by the Coordination Group on 28 November 2022 pursuant to Article 3(7), point (k), of Regulation (EU) 2021/2282, that is the subgroup on the identification of emerging health technologies (‘the EHT Subgroup’) or the subgoup on joint clinical assessments (‘the JCA Subgroup’).
Recital 5, Regulation (EU) 2024/2699
In forcesince 18 Oct 2024